Orgenesis IncChange company Symbol lookupSelect an option...ORGS Orgenesis IncARVN Arvinas IncFOUR Shift4 Payments IncUK Ucommune International LtdCRDF Cardiff Oncology IncTRNR Interactive Strength IncOMGA Omega Therapeutics IncACST Acasti Pharma IncPYPD PolyPid LtdACRX AcelRx Pharmaceuticals IncGo
Change company Symbol lookup
Select an option...
ORGS Orgenesis Inc
ARVN Arvinas Inc
FOUR Shift4 Payments Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
Health Care : Biotechnology | Small Cap Value
Company profileOrgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Postmarket |
|
|
| ||
Market Hours |
|
|
|
|
|
| Latest Earnings Missed Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 11, 2023 | -$0.15 | Q2 Consensus of 1 analysts | $0.06 | Difference from consensus | -350.00% | Q3 Earnings will announce | (Unconfirmed) November 8, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
ORGS's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.